comparemela.com

Latest Breaking News On - Over treating - Page 1 : comparemela.com

Transcripts for BBCNEWS Click - Short Edition 20240604 19:53:00

for women worldwide. and whilst five year survival rates have massively risen thanks to better treatment and better screening there is always the fear that after you ve had treatment to get rid of it, the cancer could come back. mm. but one company is using al to try and better predict recurrence rates so that people get treatments that are more suited to them. gustave roussy, in paris, is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health.

Transcripts for BBCNEWS Click - Short Edition 20240604 22:52:00

gustave roussy in paris is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them. french and us tech company owkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer.

Transcripts for BBCNEWS Click - Short Edition 20240604 03:37:00

mm. but one company is using ai to try and better predict recurrence rates so that people get treatments that are more suited to them. gustave roussy in paris is one of the world s leading cancer centres often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them.

Transcripts for BBCNEWS Breakfast 20240604 06:53:00

making it the most common cancer for women worldwide. and whilst five year survival rates have massively risen, thanks to better treatment and better screening, there is always the fear that, after you ve had treatment to get rid of it, the cancer could come back. mm, but one company is using al to try and better predict recurrence rates so that people get treatments that are more suited to them. gustave roussy in paris is one of the world s leading cancer centres, often treating rare or complex tumours, as well as trialling some of the latest diagnostics and therapies. personalising a cancer plan can be a really tough challenge, especially when it comes to the balance between providing enough treatment to avoid recurrence and over treating and the impact that that can have

Transcripts for BBCNEWS Click - Short Edition 20240604 22:53:00

and over treating and the impact that that can have on a patient s health. and here, what s known as a non interventional clinical trial is using artificial intelligence to assess the risk of recurrence. but because this is a study where long term data is vital, the patients aren t told of the al s findings to avoid the risk of life or death treatment decisions being based on them. french and us tech company 0wkin has partnered with the hospital to digitise over 1,500 tissue samples from women with breast cancer. this will provide some of the information needed to classify patients between having a high, intermediate or low risk of their disease returning within five years. we know that for this type of cancer, the prognosis is good, with more than 90% of patients being able to get rid of the disease. in these patients, we want to avoid as much as possible a heavy

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.